TABLE 2.
Main characteristics of the patient population of the studies analyzed.
| Study | SMASH-VT | VTACH | VANISH | SMS | BERLIN VT | PARTITA | SURVIVE-VT | PAUSE-SCD |
| Author | Reddy | Kuck | Sapp | Kuck | Willems | Della Bella | Arenal | Tung |
| Year | 2007 | 2010 | 2016 | 2017 | 2020 | 2022 | 2022 | 2022 |
| Sample size (n) | 128 | 107 | 259 | 111 | 159 | 47 | 144 | 121 |
| Intervention/control sample size (n) | 64/64 | 52/55 | 132/127 | 54/57 | 76/83 | 23/24 | 71/73 | 60/61 |
| Age (years) | 67 ± 9/66 ± 10 | 67.7 ± 8.3/64.4 ± 8.2 | 70.3 ± 7.3/67.0 ± 8.6 | 68.4 ± 7.7/65.9 ± 8.4 | 66 ± 10/66 ± 9 | 71.2 ± 8.1/65.6 ± 9.6 | 70 (63–75)/71 (64–76) | 51 (45.5–65)/57 (47–63) |
| Males (%) | 92/81 | 96/91 | 92.9/93.2 | 87/81 | 88.2/86.7 | 83/88 | 98.6/93.2 | 73.3/88.5 (p = 0.03) |
| NYHA class (%) (ablation/control | 84/77% in I-II; 16/23% in III-IV | NR (class IV excluded) | 77.3/75.5% in I-II; 22.7/24.4% in III | NR (class IV excluded) | 77.6/78.3% in I-II; 22.4/21.7% in III | 87/81% in I-II; 13/19% in III | 91.4/93.2% in I-II; 8.6/6.8% in III | 76.7/83.6% in I-II; 20.3/13.1% in III; 3.3/3.3% in IV |
| LVEF (%) | 30.7 ± 9.5/32.9 ± 8.5 | 34 ± 9.6/34.1 ± 8.8 | 31.2 ± 10.7/31.1 ± 10.4 | 32 ± 6.9/30.4 ± 7.3 | 41 ± 6/41 ± 6 | 31.9 ± 9/32.4 ± 8.3 | 35 (26–41)/33 (25–40) | 41 (31–60)/40 (30–48) |
| HTN (%) | 73/67 | NR | 69.3/69.7 | NR | 81.6/79.5 | 81/68 | 78.9/64.4 | 31.7/34.4 |
| DM (%) | 38/50 | NR | 31.5/28.0 | NR | 30.3/26.5 | 19/41 | 29.6/20.5 | 13.3/24.6 |
| b-blocker (%) | 94/98 | 75/75 | 93.9/96.1 | 91/91 | 76.3/71.1 | 100/100 | 97.2/86.1 | 78.3/86.9 |
| ACEI/ARB (%) | 92/92 | NR | 87.9/87.4 | 90/100 | 61.8/71.1 | 87/92 | 98.6/90.3 | 43.3/50.8 |
| MRA (%) | NR | NR | NR | NR | 23.7/25.3 | NR | 55.7/60.9 | NR |
| Amiodarone (%) | 0/0 (exclusion criterion) | 35/35 | 64.4/66.1 | 30/35 | 40.8/26.5 | 5/21 | 0/87.1 | 33.3/37.7 |
| CRT-D (%) | 0/0 | 0/0 | 22/17.3 | 9.3/10.5 | 11/3.6 | 30/33 | 15.5/18.1 | 6.7/6.6 |
| ICD implanted before the ablation | 87% | 7.7% | 100% | 11% | 0% | 100% | 95.8% | NR |
| Follow-up (months) | 22.5 ± 5.5 | 22.5 ± 9 | 27.9 ± 17.1 | 27.6 ± 13.2 | 13.2 ± 9.5 | 24.2 (8.5–24.4) | 23.8 (16.6–24)/23.3 (9.4–23.9) | 31.3 (20.1–40) |
| Cross-over to ablation (n) | NR | 12 | 11 | 1 | 8 | 1 | 18 | NR |
| Severe complications related to the study procedures(n) | 3/0 | 6/9 | 20/39 | 13/9 | 14/8 | 0/0 | 7/21 | 5/0 |
Cells with two numbers present intervention/control arms. The central tendency is presented as mean ± SD or median (IQR 25–75%). ACEI, Angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CRT-D, cardiac resynchronization therapy system with defibrillator; DM, diabetes mellitus; HTN, hypertension; ICD, implantable cardioverter-defibrillator; LVEF, left ventricular ejection fraction; MI, myocardial infarction; MRA, mineralocorticoid receptor antagonist; NA, not available/applicable; NYHA, New York Heart Association; NR, not reported.